or
Bookmark and Share
Optical radiation treatment for prevention of surgical scars
   
Document Number
US Patent 6210426
Issued Date
April 3, 2001
Link
Inventors
Map
Abstract
A method for the prevention of a scar on the skin of a patient after the beginning healing of a wound or surgical site on that patient. The method comprises the steps of providing an optical radiation apparatus with a handpiece communicating therewith, energizing the optical radiation apparatus to provide a beam of light, directing the light beam onto a wound or surgical site of a patient after 2 days and before 2 months from the date of injury or surgical procedure to the patient. The beam has a wavelength range of about 530 nm to 1000 nm and the beam has a fluence range of from 2 J/cm.sup.2 to 12 J/cm.sup.2. The beam is preferrably generated by a pulsed dye laser apparatus.
Drawing
Optical radiation treatment for prevention of surgical scars - US Patent 6210426 Drawing
Drawing from US Patent 6210426
Tags:
Description:
Amusing 0%
Clever 0%
Complex 0%
Efficient 0%
Historic 0%
Important 0%
Innovative 0%
Interesting 0%
Practical 0%
Simple 0%
Number of Claims:
10
Comments:
no comments yet
Owner
Cynosure Inc (Chelmsford, MA)
Published
April 3, 2001
Application Number
09/231,746
Filed
January 15, 1999
US Classification
607/89   128/898 606/9
Int'l Classification
A61B   18/20   (20060101)  
Assistant Examiner
Attorney/Law Firm
USPTO Field of Search
607/88   607/89   607/90   606/3   606/9   606/2   128/395   128/396   128/397   128/398  
Related Patents
6692517 - Optical radiation treatment for enhancement of wound healing - Owned by Cynosure, Inc. (Chelmsford, MA)

A method for the reduction in healing time for a wound on the skin of a mammalian patient. The method comprises the steps of providing an optical radiation apparatus with a handpiece communicating therewith, energyzing the optical radiation apparatus to provide a beam of light, and directing the light beam onto a wound or surgical site of a patient. The beam has a wavelength range of about 530 nm to 1000 nm and the beam has a fluence range of from 2 J/cm.sup.2 to 5 J/cm.sup.2. The beam is preferrably generated by a pulse dye laser apparatus.

7177695 - Early stage wound healing using electromagnetic radiation - Owned by CefamOptec Industries, Inc. (East Longmeadow, MA)

A device and method is disclosed for the treatment of early stage wounds, i.e. those wounds that have resulted in little or no breach of the skin tissue. The invention utilizes non-ablative laser or non-coherent electromagnetic radiation applied to a stage one or two wound to stimulate wound healing, destroy viral and bacterial bodies, and prevent the development of such wounds into higher stage wounds. An appropriate wavelength is chosen from the range of 193 nm to 10.6 microns, and is delivered at a power density of about at least 1 W/cm.sup.2 over a predetermined treatment duration typically in the range of 1 second to 3 minutes. To achieve the desired energy density, radiation is typically delivered at a power between 1 Watt and 15 Watts, with an average power of 5 10 Watts. Early stage wounds that can be addressed with this invention include but are not limited to spider or other insect bites, bee stings, rashes, eczema, psoriasis, and poison ivy. The present invention is especially useful for patients with a compromised ability to heal or stave off infection due to diabetes or other conditions.

6808532 - Laser treatment for reducing wrinkles

Skin including wrinkles is irradiated with laser radiation having a wavelength between about 525 and 550 nanometers. The irradiation is delivered at a fluence that stimulates wound healing responses without actually inflicting a wound. This promotes deposition of dermal extracellular matrix. Absorption properties of hemoglobin and melanin in the 525 to 550 nanometer wavelength range provide that wound healing response is concentrated close to upper regions of the skin and accordingly close to the location of the wrinkles. The growth of dermal extracellular matrix "bulks-up" irradiated dermal tissue. This makes the depressions or folds of the wrinkles shallower and less apparent.

6610052 - Laser system and method for treatment of biologic targets - Owned by Cynosure, Inc. (Chelmsford, MA)

A long pulse alexandrite laser for treating dermatological specimens is disclosed. The use of alexandrite allows operation in the near-infrared, specifically in a 50 nm range surrounding 755. Infrared in this range allows good penetration while still achieving an acceptable ratio of hemoglobin to melanin absorption. In operation, the laser generates pulses having a durations between 5 and 100 msec and fluences between 10 and 50 J/cm.sup.2. A light delivery system is provided that transmits the laser light output pulse to dermatological targets of a patient. The invention is also directed to a hair removal system. Here, it is desirable to use an index-matching application on the skin sections to be treated, and a visual indicator is thermo- or photo-responsive or otherwise responsive to the laser light pulse to generate a visible change. Also, the invention is directed to a combined sclerotherapy and light treatment method and kit for unwanted veins. Substantially increased success has been achieved by implementing a dwell time of between 12 hours and 6 months between the light-based therapy and the sclerotherapy. Finally, the invention relates to pulse periodic heating of biologic targets, including systems and methods for generating an effective light output pulse comprising a series of sub-pulses with a limited duty cycle and a periodicity that is less than the thermal relaxation time of the targeted structure.

7118562 - Laser system and method for treatment of biologic targets - Owned by Cynosure, Inc. (Westford, MA)

A long pulse alexandrite laser for treating dermatological specimens is disclosed. The use of alexandrite allows operation in the near-infrared, specifically in a 50 nm range surrounding 755. Infrared in this range allows good penetration while still achieving an acceptable ratio of hemoglobin to melanin absorption In addition, a method and related system for treating biologic tissue with pulse light includes generating a long effective output light pulse comprising a series of sub-pulses having a fractional duty cycle over a selected effective pulse duration, a periodicity that is less than the thermal relaxation time of a targeted structure, and an interpulse-delay between successive sub-pulses that is greater than the thermal relaxation time of non-targeted structures within the treatment area; and delivering the output light to the tissue of a patient.

Claims
Description
About| FAQs| Terms & Disclaimer| Link to Us| Contact Us